Medtronic PLC $MDT Shares Acquired by NEOS Investment Management LLC

NEOS Investment Management LLC grew its holdings in shares of Medtronic PLC (NYSE:MDT) by 35.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 168,306 shares of the medical technology company’s stock after purchasing an additional 44,197 shares during the period. NEOS Investment Management LLC’s holdings in Medtronic were worth $16,029,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. AXQ Capital LP raised its position in shares of Medtronic by 25.6% during the 2nd quarter. AXQ Capital LP now owns 9,890 shares of the medical technology company’s stock worth $862,000 after purchasing an additional 2,013 shares during the last quarter. UMB Bank n.a. boosted its holdings in Medtronic by 65.8% in the 3rd quarter. UMB Bank n.a. now owns 138,278 shares of the medical technology company’s stock worth $13,170,000 after buying an additional 54,898 shares during the last quarter. Applied Finance Capital Management LLC purchased a new stake in Medtronic during the 3rd quarter worth approximately $1,308,000. Principal Financial Group Inc. raised its holdings in shares of Medtronic by 17.2% during the third quarter. Principal Financial Group Inc. now owns 1,656,155 shares of the medical technology company’s stock valued at $157,732,000 after acquiring an additional 242,910 shares during the last quarter. Finally, Willis Investment Counsel lifted its position in shares of Medtronic by 5.0% in the third quarter. Willis Investment Counsel now owns 401,868 shares of the medical technology company’s stock valued at $38,274,000 after acquiring an additional 19,192 shares in the last quarter. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several analysts recently commented on the company. Citigroup initiated coverage on Medtronic in a research report on Tuesday, February 3rd. They set a “buy” rating and a $117.00 price target for the company. Wells Fargo & Company initiated coverage on shares of Medtronic in a report on Friday, January 30th. They set an “overweight” rating and a $114.00 target price for the company. Robert W. Baird set a $103.00 target price on shares of Medtronic in a research report on Tuesday, December 16th. JPMorgan Chase & Co. raised their price target on shares of Medtronic from $90.00 to $100.00 and gave the stock a “neutral” rating in a research note on Thursday, November 13th. Finally, Leerink Partners set a $120.00 price target on shares of Medtronic and gave the stock an “outperform” rating in a research report on Wednesday, November 19th. Sixteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $111.21.

Medtronic Trading Down 3.2%

Shares of MDT opened at $96.33 on Wednesday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The firm has a 50-day moving average price of $99.19 and a 200 day moving average price of $96.58. The firm has a market capitalization of $123.50 billion, a P/E ratio of 25.96, a P/E/G ratio of 2.62 and a beta of 0.71.

Medtronic (NYSE:MDT) last issued its earnings results on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, topping analysts’ consensus estimates of $1.34 by $0.02. The company had revenue of $9.02 billion for the quarter, compared to the consensus estimate of $8.89 billion. Medtronic had a net margin of 13.71% and a return on equity of 14.86%. Medtronic’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts forecast that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, January 16th. Investors of record on Friday, December 26th were issued a $0.71 dividend. The ex-dividend date was Friday, December 26th. This represents a $2.84 dividend on an annualized basis and a yield of 2.9%. Medtronic’s dividend payout ratio is currently 76.55%.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Q3 beat — Medtronic exceeded consensus on revenue (~$9.02B) and adjusted EPS ($1.36), driven by robust demand for heart devices and diabetes monitors, supporting the bullish growth story. Medtronic beats quarterly profit estimates on robust demand for heart devices
• Positive Sentiment: Strong segment performance — Cardiovascular (including cardiac ablation/PFA) and Diabetes delivered outsized growth (cardiac ablation growth cited very strong), making this one of the company’s best quarters in recent years and underpinning revenue momentum. Medtronic reports strong third quarter fiscal 2026 results with highest enterprise revenue growth in 10 quarters
• Positive Sentiment: Regulatory/product wins — FDA clearance and immediate commercial activity for the Hugo™ robotic system (first U.S. case performed) and clearances for other surgical/spine systems expand addressable markets and could accelerate procedure volumes. Medtronic announces first surgery with Hugo™ robotic-assisted surgery system in the U.S. performed at Cleveland Clinic
• Positive Sentiment: Additional approvals and pipeline progress — FDA nod for Infuse bone graft in TLIF procedures and MiniMed Flex submission keep product catalysts on the calendar for surgical and diabetes franchises. Medtronic gets FDA nod for Infuse bone graft in TLIF procedures
• Neutral Sentiment: Guidance reiterated — Management reaffirmed FY26 organic revenue and EPS guidance (EPS range ~5.620–5.660), which was neither a downside shock nor a strong upside catalyst; investors are parsing precision of margins and timing of improvement. Medtronic Reaffirms 2026 Outlook As Heart and Diabetes Units Drive Growth
• Neutral Sentiment: Technicals/analyst outlook — Technical analysts and MarketBeat highlight a “textbook” reversal and institutional accumulation that imply upside targets in the $118–$125 range; this is supportive longer term but doesn’t offset near‑term margin concerns. Medtronic’s “Textbook” Reversal: How High Can It Really Go in 2026?
• Negative Sentiment: Margin pressures and costs — Investors reacted to margin contraction (tariffs, higher costs, and investments) and reports that GAAP profit fell despite higher revenue; these near‑term profitability headwinds help explain the stock decline. Medtronic Profit Falls Despite Higher Revenue

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).